樂觀
$12.55
情境價格
$23.640
+0.099 (+0.42%)收盤時
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.
Tactile Systems Technology Inc is a good buy right now at a current price of $23.64, especially considering its strong revenue growth of 57.60% over the past year and a solid gross margin of 75.50% in Q2 2026. The RSI is at 67.38, indicating bullish momentum, and the forward P/E ratio of 19.12 suggests it is reasonably valued compared to its growth prospects. However, the main risk is the recent decline of 13.72% year-to-date, which reflects market volatility and potential earnings challenges ahead.
BTIG
$35
2026-10-12
BTIG
2026-10-12
目標價
$35
B. Riley
$36
2026-05-07
B. Riley
2026-05-07
目標價
$36
BTIG
$40
2026-05-05
BTIG
2026-05-05
目標價
$40
BTIG
$38
2026-02-18
BTIG
2026-02-18
目標價
$38
B. Riley
$32
2026-02-18
B. Riley
2026-02-18
目標價
$32
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Tactile Systems Reports 9% Revenue Growth in Q2 Earnings Call

Tactile Systems Technology Shares Rise 8.1% on Strong Volume

Tactile Systems Technology Reports Strong Q1 2026 Earnings Growth

Tactile Systems (TCMD) Q1 2026 Earnings Transcript

Tactile Systems Reports Strong Earnings, Stock Surges 18%
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Tactile Systems Technology Inc is a good buy right now at a current price of $23.64, especially considering its strong revenue growth of 57.60% over the past year and a solid gross margin of 75.50% in Q2 2026. The RSI is at 67.38, indicating bullish momentum, and the forward P/E ratio of 19.12 suggests it is reasonably valued compared to its growth prospects. However, the main risk is the recent decline of 13.72% year-to-date, which reflects market volatility and potential earnings challenges ahead.
6 analysts cover TCMD: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.67.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。